Literature DB >> 15093907

Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma.

Paul D Brown1, Jan C Buckner, Judith R O'Fallon, Nancy L Iturria, Brian P O'Neill, Cerise A Brown, Bernd W Scheithauer, Robert P Dinapoli, Robert M Arusell, Walter J Curran, Ross Abrams, Edward G Shaw.   

Abstract

PURPOSE: The outcome and cognitive performance data collected in a prospective, intergroup clinical trial were analyzed to assess the prognostic importance of the baseline (before radiotherapy) Mini-Mental State Examination (MMSE) score in patients with low-grade glioma. METHODS AND MATERIALS: The patients studied were 203 adults with a supratentorial low-grade glioma randomly assigned to low-dose (50.4 Gy in 28 fractions) or high-dose (64.8 Gy in 36 fractions) localized radiotherapy. Folstein MMSE scores and neurologic function scores at baseline in combination with multiple other baseline variables were analyzed. The median follow-up was 7.4 years for the 101 patients still alive.
RESULTS: Patients (n = 36) with an abnormal baseline MMSE score (< or =26) had a worse 5-year progression-free survival rate (27% vs. 60%; p <0.001) and overall survival rate (31% vs. 76%; p <0.001) compared with those with a normal score. On multivariate analysis, the baseline MMSE score was a statistically significant predictor of survival. Other factors associated with overall survival were age, tumor size, and tumor histologic type.
CONCLUSION: The presence of an abnormal baseline MMSE score was a strong predictor of poorer progression-free and overall survival for patients with a low-grade glioma. The baseline MMSE should be considered in future prognostic scoring systems.

Entities:  

Mesh:

Year:  2004        PMID: 15093907     DOI: 10.1016/j.ijrobp.2003.10.040

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  26 in total

1.  Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial.

Authors:  Anthony Pham; Menachem Z Yondorf; Bhupesh Parashar; Ronald J Scheff; Susan C Pannullo; Rohan Ramakrishna; Philip E Stieg; Theodore H Schwartz; A Gabriella Wernicke
Journal:  J Neurooncol       Date:  2015-12-09       Impact factor: 4.130

2.  The association between cognitive functioning and health-related quality of life in low-grade glioma patients.

Authors:  Florien W Boele; Maaike Zant; Emma C E Heine; Neil K Aaronson; Martin J B Taphoorn; Jaap C Reijneveld; Tjeerd J Postma; Jan J Heimans; Martin Klein
Journal:  Neurooncol Pract       Date:  2014-05-06

3.  Predicting compliance and survival in palliative whole-brain radiotherapy for brain metastases.

Authors:  Sebastià Sabater; Encarna Mur; Katrin Müller; Meritxell Arenas
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

4.  Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.

Authors:  Barbara J Fisher; Chen Hu; David R Macdonald; Glenn J Lesser; Stephen W Coons; David G Brachman; Samuel Ryu; Maria Werner-Wasik; Jean-Paul Bahary; Junfeng Liu; Arnab Chakravarti; Minesh Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-01-30       Impact factor: 7.038

Review 5.  Low-grade gliomas: the debate continues.

Authors:  Paul D Brown
Journal:  Curr Oncol Rep       Date:  2006-01       Impact factor: 5.075

Review 6.  Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities.

Authors:  Martin Klein
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

7.  New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials.

Authors:  Thierry Gorlia; Wenting Wu; Meihua Wang; Brigitta G Baumert; Minesh Mehta; Jan C Buckner; Edward Shaw; Paul Brown; Roger Stupp; Evanthia Galanis; Denis Lacombe; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2013-09-18       Impact factor: 12.300

8.  Neurocognitive training in patients with high-grade glioma: a pilot study.

Authors:  Marco Ronald Hassler; Katarzyna Elandt; Matthias Preusser; Johann Lehrner; Petra Binder; Karin Dieckmann; Andrea Rottenfusser; Christine Marosi
Journal:  J Neurooncol       Date:  2009-09-10       Impact factor: 4.130

9.  Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials.

Authors:  Sarah K Lageman; Jane H Cerhan; Dona E C Locke; S Keith Anderson; Wenting Wu; Paul D Brown
Journal:  J Neurooncol       Date:  2009-07-19       Impact factor: 4.130

10.  Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic.

Authors:  David A Schomas; Nadia N Laack; Paul D Brown
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.